Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia
Launched by MEIRAGTX, LLC · Aug 5, 2024
Trial Information
Current as of August 11, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Individual participation in this study will last approximately 48 months for participants who received AAV2-hAQP1 in Study MGT-AQP1-201 and at least 60 months for participants who receive AAV2-hAQP1 in Study MGT-AQP1-202.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Received study drug in Study MGT-AQP1-201
- Exclusion Criteria:
- • Withdrew consent to participate in Study MGT-AQP1-201.
About Meiragtx, Llc
MeiraGtx, LLC is a biopharmaceutical company focused on developing innovative gene therapies to address unmet medical needs in rare and prevalent diseases. With a commitment to advancing cutting-edge scientific research, MeiraGtx leverages its proprietary technologies to create transformative treatments that target the underlying causes of genetic disorders. The company is dedicated to improving patient outcomes through rigorous clinical trials and collaborations with leading scientific and medical communities. MeiraGtx aims to enhance the quality of life for patients by delivering safe and effective gene therapies that have the potential to revolutionize the treatment landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Charlotte, North Carolina, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported